Arvinas, Inc. (NASDAQ:ARVN) Insider Sells $150,724.20 in Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Arvinas Price Performance

Shares of ARVN opened at $17.26 on Friday. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.23 and a beta of 1.88. Arvinas, Inc. has a 1-year low of $16.07 and a 1-year high of $51.51. The company has a 50-day moving average of $18.37 and a 200 day moving average of $22.72.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the business earned ($2.53) earnings per share. On average, equities analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on ARVN shares. HC Wainwright reissued a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. BMO Capital Markets restated an “outperform” rating and issued a $82.00 price target (down from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Guggenheim reaffirmed a “buy” rating and set a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus reduced their target price on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

Hedge Funds Weigh In On Arvinas

A number of hedge funds and other institutional investors have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. bought a new stake in shares of Arvinas in the fourth quarter valued at about $28,000. KBC Group NV increased its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Arvinas during the fourth quarter valued at approximately $171,000. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.